Synergistic inhibitory effects of atriopeptin II and isoproterenol on contraction of rat aortic smooth muscle: roles of cGMP and cAMP

Eur J Pharmacol. 1993 Dec 21;250(3):477-81. doi: 10.1016/0014-2999(93)90038-j.


Atriopeptin II and isoproterenol acted synergistically to inhibit the phenylephrine-induced contraction of aortic smooth muscle from Wistar-Kyoto (WKY) rats. Thus, a weakly inhibitory concentration of atriopeptin II (10 nM) caused a 5-fold decrease in the IC50 of isoproterenol from 169 nM to 32 nM, whereas a low concentration of isoproterenol (100 nM) increased the maximum inhibition attributable to atriopeptin II from 43% to 74%. Atriopeptin II (10 nM) increased the cGMP found in aortic smooth muscle and approximately doubled the accumulation of cAMP caused by isoproterenol. The results suggest that cGMP, formed by the action of atriopeptin II on receptor guanylyl cyclase (GC-A), may inhibit aortic cyclic nucleotide phosphodiesterase type III (PDE III) and that an increased accumulation of cAMP then mediates the observed synergism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Aorta / drug effects
  • Atrial Natriuretic Factor / pharmacology*
  • Cyclic AMP / metabolism*
  • Cyclic GMP / metabolism*
  • Drug Synergism
  • In Vitro Techniques
  • Isoproterenol / pharmacology*
  • Male
  • Muscle Contraction / drug effects
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / physiology
  • Peptide Fragments
  • Rats
  • Rats, Inbred WKY
  • Vasoconstriction / drug effects


  • Peptide Fragments
  • Atrial Natriuretic Factor
  • atrial natriuretic factor prohormone (103-125)
  • Cyclic AMP
  • Cyclic GMP
  • Isoproterenol